余东阳,张申华,韩丽蓉.MiRNA-22在不同分期浆液性卵巢腺癌中的表达以及与化疗药物耐药性关系的研究[J].肿瘤学杂志,2016,22(12):993-997.
MiRNA-22在不同分期浆液性卵巢腺癌中的表达以及与化疗药物耐药性关系的研究
Expression of MiRNA-22 in Serous Ovarian Adenocarcinoma of Different Stages and Its Relation to Chemotherapy Drug Resistance
投稿时间:2016-06-23  
DOI:10.11735/j.issn.1671-170X.2016.12.B003
中文关键词:  卵巢肿瘤  腺癌  miRNA-22  耐药  药物疗法
英文关键词:ovarian neoplasms  adenocarcinoma  miRNA-22  drug resistance  drug therapy
基金项目:
作者单位
余东阳 天门市第一人民医院 
张申华 天门市第一人民医院 
韩丽蓉 天门市第一人民医院 
摘要点击次数: 2018
全文下载次数: 603
中文摘要:
      摘 要:[目的] 探讨miRNA-22在不同分期浆液性卵巢腺癌的表达以及与化疗耐药性关系。[方法] 使用基因芯片技术筛选出差异化表达的miRNA,再用实时荧光定量聚合酶链反应(RT-PCR)检测miRNA-22在人卵巢癌细胞株(SKOV3)、紫杉醇稳定耐药卵巢浆液性囊腺癌细胞亚株(SKOV3-TR30)、人正常卵巢上皮细胞株(IOSE80)及50例确诊为浆液性卵巢腺癌的患者、25例正常人血清中的表达水平,并分析其与患者临床分期的关系以及用药前后的关系。[结果] miRNA-22在SKOV3-TR30耐药株中的表达明显高于SKOV3敏感株中的表达水平(P<0.05),IOSE80正常卵巢上皮细胞株中miRNA-22的表达水平明显低于SKOV3敏感株(P<0.05);在FIGO手术病理不同分期中的表达,Ⅰ、Ⅱ、Ⅲ、Ⅳ期表达水平依次增高;经统一的化疗方案治疗后,化疗无效组的表达水平高于化疗有效组的表达水平(P<0.05)。[结论] miRNA-22可能是卵巢癌患者潜在的肿瘤标志物,miRNA-22的高表达可能与癌细胞的过度增殖与转移、侵袭有关,具有癌基因与抑癌基因的双侧作用,且可能与化疗药物的耐药性密切相关。
英文摘要:
      Abstract:[Objective] To investigate the expression of miRNA-22 in serous ovarian adenocarcinoma of different stages and its relation to chemotherapy drug resistance. [Methods] The differential expression of microRNA was screened using the gene chip technique,and then RT-PCR was used to detect the expression of miRNA-22 in ovarian cancer SKOV3 and SKOV3-TR30,normal ovarian epithelial IOSE80 cells and in serum of 50 patients with serous ovarian adenocarcinoma and 25 healthy women. The correlation of miRNA-22 expression with serous ovarian adenocarcinoma of different stages was analyzed before and after treatment. [Results] The expression of miRNA-22 in chemoresistant SKOV3-TR30 cells was significantly higher than that in sensitive SKOV3 cells(P<0.05),and the expression in normal ovarian epithelial IOSE80 cells was significantly lower than that in the SKOV3 sensitive cells(P<0.05). The expression of miRNA-22 in different FIGO surgical-pathological stages was increased from stage Ⅰ,Ⅱ,Ⅲ to stage Ⅳ. After treatment with the unified chemotherapy regimens,the expression level in non-response group was higher than that in response group(P<0.05). [Conclusion] MiRNA-22 might be a potential tumor marker in patients with ovarian cancer,the high expression of miRNA-22 may be closely related to excessive proliferation and metastasis,invasion of serous ovarian adenocarcinoma cells,and it also may be closely related to the chemotherapy drug resistance.
在线阅读   查看全文  查看/发表评论  下载PDF阅读器